62 related articles for article (PubMed ID: 25007143)
21. Atypical Histopathological Aspects of Common Types of Lung Cancer-Our Experience and Literature Review.
Marghescu AȘ; Leonte DG; Radu AD; Măgheran ED; Tudor AV; Teleagă C; Țigău M; Georgescu L; Costache M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256374
[TBL] [Abstract][Full Text] [Related]
22. Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts.
Boland JM; Wampfler JA; Jang JS; Wang X; Erickson-Johnson MR; Oliveira AM; Yang P; Jen J; Yi ES
Am J Surg Pathol; 2014 Dec; 38(12):1681-8. PubMed ID: 25007143
[TBL] [Abstract][Full Text] [Related]
23. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
Grosse A; Grosse C; Rechsteiner M; Soltermann A
Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
[TBL] [Abstract][Full Text] [Related]
24. Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.
Pareja F; Crapanzano JP; Mansukhani MM; Bulman WA; Saqi A
Cancer Cytopathol; 2015 Mar; 123(3):162-70. PubMed ID: 25557162
[TBL] [Abstract][Full Text] [Related]
25. Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung.
Ou SH; Ziogas A; Zell JA
J Thorac Oncol; 2010 Apr; 5(4):420-7. PubMed ID: 20130484
[TBL] [Abstract][Full Text] [Related]
26. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
27. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
[TBL] [Abstract][Full Text] [Related]
28. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas.
Sholl LM; Sun H; Butaney M; Zhang C; Lee C; Jänne PA; Rodig SJ
Am J Surg Pathol; 2013 Sep; 37(9):1441-9. PubMed ID: 23887156
[TBL] [Abstract][Full Text] [Related]
29. Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib.
Bos M; Gardizi M; Schildhaus HU; Heukamp LC; Geist T; Kaminsky B; Zander T; Nogova L; Scheffler M; Dietlein M; Kobe C; Holstein A; Maintz D; Büttner R; Wolf J
Lung Cancer; 2013 Jul; 81(1):142-3. PubMed ID: 23558310
[TBL] [Abstract][Full Text] [Related]
30. MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases.
Boland JM; Jang JS; Li J; Lee AM; Wampfler JA; Erickson-Johnson MR; Soares I; Yang P; Jen J; Oliveira AM; Yi ES
J Thorac Oncol; 2013 May; 8(5):574-81. PubMed ID: 23449277
[TBL] [Abstract][Full Text] [Related]
31. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
[TBL] [Abstract][Full Text] [Related]
32. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer.
Davies KD; Le AT; Theodoro MF; Skokan MC; Aisner DL; Berge EM; Terracciano LM; Cappuzzo F; Incarbone M; Roncalli M; Alloisio M; Santoro A; Camidge DR; Varella-Garcia M; Doebele RC
Clin Cancer Res; 2012 Sep; 18(17):4570-9. PubMed ID: 22919003
[TBL] [Abstract][Full Text] [Related]
33. ROS1 rearrangements define a unique molecular class of lung cancers.
Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
[TBL] [Abstract][Full Text] [Related]
34. Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.
Yang P; Kulig K; Boland JM; Erickson-Johnson MR; Oliveira AM; Wampfler J; Jatoi A; Deschamps C; Marks R; Fortner C; Stoddard S; Nichols F; Molina J; Aubry MC; Tang H; Yi ES
J Thorac Oncol; 2012 Jan; 7(1):90-7. PubMed ID: 22134072
[TBL] [Abstract][Full Text] [Related]
35. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.
Yoshida A; Tsuta K; Watanabe S; Sekine I; Fukayama M; Tsuda H; Furuta K; Shibata T
Lung Cancer; 2011 Jun; 72(3):309-15. PubMed ID: 21036415
[TBL] [Abstract][Full Text] [Related]
36. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.
Sun Y; Ren Y; Fang Z; Li C; Fang R; Gao B; Han X; Tian W; Pao W; Chen H; Ji H
J Clin Oncol; 2010 Oct; 28(30):4616-20. PubMed ID: 20855837
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]